Adamas Pharmaceuticals Inc (ADMS) Receives Average Recommendation of “Buy” from Analysts

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has been assigned a consensus recommendation of “Buy” from the twelve research firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $45.67.

A number of equities research analysts have commented on the company. Zacks Investment Research raised Adamas Pharmaceuticals from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a research note on Wednesday, January 3rd. Cowen set a $55.00 price objective on Adamas Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, December 13th. Northland Securities assumed coverage on Adamas Pharmaceuticals in a research note on Wednesday, November 29th. They issued an “outperform” rating for the company. BidaskClub cut Adamas Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 14th. Finally, Piper Jaffray Companies set a $52.00 price objective on Adamas Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, December 19th.

A number of institutional investors have recently made changes to their positions in ADMS. Schwab Charles Investment Management Inc. lifted its holdings in shares of Adamas Pharmaceuticals by 11.7% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 30,690 shares of the specialty pharmaceutical company’s stock valued at $1,041,000 after purchasing an additional 3,218 shares in the last quarter. Point72 Asset Management L.P. lifted its holdings in shares of Adamas Pharmaceuticals by 639.3% in the third quarter. Point72 Asset Management L.P. now owns 850,165 shares of the specialty pharmaceutical company’s stock valued at $17,998,000 after purchasing an additional 735,165 shares in the last quarter. Granite Point Capital Management L.P. lifted its holdings in shares of Adamas Pharmaceuticals by 26.6% in the third quarter. Granite Point Capital Management L.P. now owns 333,515 shares of the specialty pharmaceutical company’s stock valued at $7,061,000 after purchasing an additional 70,000 shares in the last quarter. Axiom International Investors LLC DE lifted its holdings in shares of Adamas Pharmaceuticals by 134.1% in the third quarter. Axiom International Investors LLC DE now owns 236,209 shares of the specialty pharmaceutical company’s stock valued at $5,001,000 after purchasing an additional 135,297 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Adamas Pharmaceuticals by 13,028.4% in the third quarter. JPMorgan Chase & Co. now owns 136,273 shares of the specialty pharmaceutical company’s stock valued at $2,839,000 after purchasing an additional 135,235 shares in the last quarter. 79.40% of the stock is owned by hedge funds and other institutional investors.

Adamas Pharmaceuticals (NASDAQ ADMS) traded up $0.80 during midday trading on Friday, reaching $38.19. The company had a trading volume of 473,006 shares, compared to its average volume of 654,331. Adamas Pharmaceuticals has a fifty-two week low of $13.50 and a fifty-two week high of $38.75. The firm has a market capitalization of $869.93, a PE ratio of -11.37 and a beta of 1.13. The company has a quick ratio of 8.32, a current ratio of 8.35 and a debt-to-equity ratio of 0.41.

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.03). During the same period last year, the business earned ($0.66) earnings per share. The business’s quarterly revenue was down 99.3% compared to the same quarter last year. sell-side analysts predict that Adamas Pharmaceuticals will post -3.84 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Adamas Pharmaceuticals Inc (ADMS) Receives Average Recommendation of “Buy” from Analysts” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/19/adamas-pharmaceuticals-inc-adms-receives-average-recommendation-of-buy-from-analysts.html.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply